Investor Overview

Board of Directors

Ronald Matricaria
Director, Chairman of the Board

Mr. Matricaria was appointed to the Board in March 2014. He has more than 35 years of medical device and pharmaceutical experience at St. Jude Medical, Inc. and Eli Lilly and Company, Inc. From April 1993 to May 1999, Mr. Matricaria served as President and Chief Executive Officer of St. Jude Medical, Inc. and served as Chairman of the Board of Directors from January 1995 to May 2002. Prior to joining St. Jude Medical, he spent 23 years with Eli Lilly and Company, Inc., where his last position was Executive Vice President of the Pharmaceutical Division of Eli Lilly and Company and President of its North American operations. He currently serves as a director of Kinaxis Inc and until recently served as Chairman of the Board at Volcano Corporation and as a member of the Boards of Phoenix Children’s Hospital and Life Technologies Corporation. Additionally, he previously served on a number of other public and private companies boards including Home Depot Inc., Diametric Medical Inc., Ceridian Inc., Centocor Inc., Haemonetics Inc., Kinetic Concepts, Inc., Hospira Inc., Cyberonics Inc., Vistacare Inc., Advanced Medical Technology Association (AdvaMed), the Pharmaceutical Manufacturers Association International Section, the American Diabetes Association, the American Foundation for Pharmaceutical Education, the National Foundation for Infectious Diseases, the National Retiree Volunteer Center and the Indiana Repertory Theatre as well as a trustee on the board of the Massachusetts College of Pharmacy and Allied Health Science. He remains a Trustee emeritus of the University of Minnesota Foundation. Mr. Matricaria holds a bachelor’s degree in pharmacy from the Massachusetts College of Pharmacy, as well as an honorary PharmD degree, in recognition of his contributions to the practice of pharmacy.

John Sicard

Mr. Sicard joined the Board in March 2018. He currently serves as the President and Chief Executive Officer, and a Board Member of Kinaxis, a global supply chain management software company that delivers cloud-based solutions to some of the world’s largest manufacturing companies, including many in the life sciences sector. Mr. Sicard joined Kinaxis in 1994 where he has held a number of senior management roles including Chief Product Officer, Chief Strategy Officer, Chief Operating Officer, Executive Vice President of Marketing Development and Service Operations and Vice President of Professional Services. Prior to Kinaxis, Mr. Sicard held positions at FastMAN Software Systems, and Monenco Agra. Mr. Sicard is a graduate of Concordia University, Montreal, Canada, and the Harvard Business School Advanced Management Program.

Mike Paolucci
Director, Chair of the Compensation Committee

Mr. Paolucci was named to the Board of Directors and appointed to the Compensation Committee in March 2016. A seasoned Human Resource (HR) executive, he has more than 20 years of global experience working directly with Boards of Directors and C-level executives to improve organizational capabilities and HR programs that result in sustained improvements in business performance. Mr. Paolucci currently serves as the Vice President and Chief Human Resources Officer for Halozyme Therapeutics Inc., a late stage oncology and biopharmaceutical company. Prior to Halozyme, he served as Executive Vice President and Chief Human Resource Officer for CareFusion. Mr. Paolucci also served as Executive Vice President of Human Resources at NuVasive, and spent five years at Life Technologies. Previously, he was head of Human Resources for the services division of Hewlett Packard and served in several leadership roles with EDS, which was acquired by Hewlett Packard. Prior to HP/EDS, Mr. Paolucci was a partner with the HR consulting firm Towers Perrin. Mr. Paolucci is a graduate of Ohio State University.


James Hinrichs
Director, Chair of the Audit & Finance Committee

Mr. Hinrichs was appointed to the Board in April 2014. He currently serves as Chief Financial Officer of Cibus, a privately-held agricultural biotech company. Prior to this Mr. Hinrichs served as Executive Vice President and Chief Financial Officer of Alere Inc, a publicly traded diagnostic company. From December 2010 through March 2015, he served as Chief Financial Officer of CareFusion Corporation, prior to its sale to Becton Dickinson. At CareFusion, he served as Senior Vice President, Global Customer Support, and  Senior Vice President, Controller. Prior to joining CareFusion when it was spun off from Cardinal Health, Inc., he worked at Cardinal Health in various positions including Executive Vice President and Corporate Controller of Cardinal Health, and as Executive Vice President and Chief Financial Officer of its Healthcare Supply Chain Services segment. He joined Cardinal Health following more than a decade of finance and marketing roles at Merck & Co. He holds undergraduate and graduate degrees in business from Carnegie Mellon University.

Alexis Lukianov

Mr. Lukianov joined the Board in December 2016. With more than 30 years’ experience in the orthopedics industry, he is currently the Chairman and CEO of Tissue Differentiation Intelligence, LLC, a privately-held ultrasound spine company. He previously served as Chief Executive Officer and Chairman of the Board of NuVasive, Inc. from 2004-2015. Mr. Lukianov was a founder of and served as Chairman of the Board and CEO of BackCare Group, Inc. Prior to this he held a variety of senior executive positions, including President, with Sofamor Danek, Inc., and director of a business unit at Smith & Nephew Orthopaedics that brought limb lengthening technology to the United States from Russia. Mr. Lukianov has previously served on the boards and the executive committees of BIOCOM, a regional life sciences trade association, the Medical Device Manufacturers Association (MDMA), a national trade association, and the California Health Institute (CHI). Mr. Lukianov also serves on a number of private and non-profit boards.

Lilly Marks

Ms. Marks joined the Board in June 2015. She currently serves as the Vice President for Health Affairs for the University of Colorado and Anschutz Medical Campus, which includes the University’s Schools of Medicine, Dental Medicine, Pharmacy, Public Health, College of Nursing and Graduate School and the University of Colorado Hospital and Children’s Hospital Colorado. Prior to her health campus leadership role, Ms. Marks spent two decades as both Senior Associate Dean for Finance and Administration at the School Of Medicine and Executive Director of University Physicians, Inc., the 501(c)(3) faculty practice plan. She has served as Chair of the Board of Directors of the University of Colorado Hospital and is currently a member of the Board of Directors of the UCHealth System, Children’s Hospital Colorado, Federal Reserve Bank of Kansas City, the Advisory Board for Clinical Research of the National Institutes of Health, the Fitzsimons Redevelopment Authority, the Association of Academic Health Centers (AAHC), the Global Down Syndrome Foundation, and the Rose Community Foundation. She is also a member of the AAMC Advisory Panel on Research and is a trustee of the University of Colorado Foundation. Ms. Marks is a graduate of the University of Colorado.

Jon Serbousek
Director, President, and Chief Executive Officer
Mr. Serbousek joined Orthofix in August 2019 and became director, President and CEO in November 2019. A seasoned executive with more than 30 years’ experience in the medical device and biotech industries, Mr. Serbousek served in several leadership positions at Biomet Inc., including Worldwide President of Biomet Biologics, Worldwide Group President of Orthopedics, and President of U.S. Orthopedics. Prior to joining Biomet, he held various general management positions within Medtronic Inc., including Worldwide Division President − Spine, and Worldwide Vice President and General Manager of Biologics for their Spine and Biologics business. Additionally, Mr. Serbousek spent 13 years with DePuy Orthopedics, a Johnson & Johnson company where he served in numerous roles of increasing responsibility, including Vice President of Marketing and Product Development and Vice President of Spinal Operations. Mr. Serbousek has held numerous board positions at for profit and not-for-profit organizations. He earned his BS in Engineering from Washington State University, his MS in Bioengineering from the University of Utah, and later completed several advanced management programs including a program at the IMD International School of Management in Lausanne, Switzerland.
Maria Sainz
Director, Chair of the Compliance Committee

Ms. Sainz became a director of Orthofix in November 2012, after previously having served on the Board from June 2008 to September 2011. Currently, she is the President and CEO of AEGEA Medical, Inc., a privately-held women’s health company in the field of endometrial ablation. Previously, Ms. Sainz served as the President, Chief Executive Officer, and Director of CardioKinetix Inc., a heart failure related medical device company. Prior to this, she was the President and Chief Executive Officer of Concentric Medical, Inc. up to and during its acquisition by Stryker Corporation in October 2011. Upon this acquisition, Ms. Sainz served as General Manager of the Stryker Neurovascular business unit. From 2003 to 2006, she was the President of the Cardiac Surgery division of Guidant Corporation. After Boston Scientific acquired Guidant, Ms. Sainz led the integration process for both the Cardiac Surgery and European Cardiac Rhythm Management business of Guidant into Boston Scientific. Between 2001 and 2003, she was the Vice President of Global Marketing–Vascular Intervention of Guidant. Ms. Sainz earned a Bachelor and Masters of Arts from the Universidad Complutense de Madrid and a Master’s Degree in International Management from American Graduate School of International Management. She has served as a director of Halyard Health, Inc. since February 2015 and of Iridex Corporation since April 2018. Ms. Sainz previously served as a director of The Spectranetics Corporation from 2010 until its sale in August 2017, and of MRI Interventions, Inc. from January 2014 to May 2018.

For recent transactions, including derivative transactions, see our Section 16 SEC filings page.